Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Her-2 Negative Metastatic Breast Cancer
  • Age: Between 18 - 90 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Histologically confirmed adenocarcinoma of the breast that is either TNBC or HER-2 negative.
    2. Received 0-2 lines of cytotoxic chemotherapy for metastatic breast cancer endocrine therapy and/or targeted therapy is allowed.
    3. Must have less than or equal to Grade 1 pre-existing peripheral neuropathy (as per CTCAE).

You may not be eligible for this study if the following are true:

    1. Hypersensitivity to pembrolizumab or any of its excipients.
    2. Has a known additional malignancy that progressed or required treatment within the last five years (exception:  basal cell carcinoma of the skin or squamous cell carcinoma of the skin or in situ cervical cancer)
    3. Patients with known active central nervous system metastases and/or carcinomatous meningitis
    4. Taxane therapy within 3 months.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.